

# Health-care workers with COVID-19 living in Mexico City: clinical characterization and related outcomes

Neftali Eduardo Antonio-Villa MD<sup>1</sup>, Omar Yaxmehen Bello-Chavolla MD, PhD<sup>2</sup>, Arsenio Vargas-Vázquez<sup>1</sup>, Carlos A. Fermín-Martínez<sup>1</sup>, Alejandro Márquez-Salinas<sup>1</sup>, Jessica Paola Bahena-López MD<sup>1</sup>

<sup>1</sup>MD/PhD (PECEM), Faculty of Medicine, National Autonomous University of Mexico.

<sup>2</sup>Division of Research, Instituto Nacional de Geriatria.

**Short title:** Health-Care Workers with SARS-CoV-2 in Mexico City

## **Corresponding author**

Omar Yaxmehen Bello-Chavolla. Division of Research. Instituto Nacional Geriatria. Anillo Perif. 2767, San Jerónimo Lídice, La Magdalena Contreras, 10200, Mexico City, Mexico. Phone: +52 (55) 5548486885. E-mail: [oyaxbell@yahoo.com.mx](mailto:oyaxbell@yahoo.com.mx)

**CONFLICT OF INTERESTS:** Nothing to disclose.

**FUNDING:** This research received no specific funding

**Word count:** 2,598 words; 3 Figures, 1 Table, 32 references.

## **ABSTRACT (250 WORDS)**

**BACKGROUND:** Health-care workers (HCWs) have increased risk for SARS-CoV-2 infection. Information about the prevalence and risk factors for adverse outcomes in HCWs is scarce in Mexico. Here, we aimed to explore prevalence of SARS-CoV-2, symptoms, and risk factors associated with adverse outcomes in HCWs in Mexico City.

**METHODS:** We explored data collected by the National Epidemiological Surveillance System in Mexico City. All cases underwent real-time RT-PCR test. We explored outcomes related to severe COVID-19 in HCWs and the diagnostic performance of symptoms to detect SARS-CoV-2 infection in HCWs.

**RESULTS:** As of July 2nd, 2020, 34,263 HCWs were tested for SARS-CoV-2 and 10,925 were confirmed (31.9%). Overall, 4,200 were nurses (38.4%), 3,244 physicians (29.7%), 126 dentists (1.15%) and 3,355 laboratory personnel and other HCWs (30.7%). After follow-up, 992 HCWs required hospitalization (9.08%), 206 developed severe outcomes (1.89%), and 90 required mechanical-ventilatory support (0.82%). Lethality was recorded in 224 (2.05%) cases. Symptoms associated with SARS-CoV-2 positivity were fever, cough, malaise, shivering, myalgias at evaluation but neither had significant predictive value. We also identified 333 asymptomatic SARS-CoV-2 infections (3.05%). Older HCWs with chronic non-communicable diseases, pregnancy, and severe respiratory symptoms were associated with higher risk for adverse outcomes. Physicians had higher risk for hospitalization and for severe outcome compared with nurses and other HCWs.

**CONCLUSIONS:** We report a high prevalence of SARS-CoV-2 in HCWs in Mexico City. No symptomatology can accurately discern HCWs with SARS-CoV-2 infection. Particular attention should focus on HCWs with risk factors to prevent adverse outcomes and reduce infection risk.

**Keywords:** COVID-19; SARS-CoV-2; Health-Care Workers; Mortality; Mexico

## INTRODUCTION

The pandemic caused by the SARS-CoV-2 has created new challenges in health-care systems worldwide (1). Recently, the pandemic has had significant increase in the number of cases in the Americas, where it has led to increase pressure on health-care facilities and led to a substantial number of deaths (2,3). Health-care workers (HCWs) have a fundamental role in caring and managing patients with COVID-19, being the primary workers involved in the daily management of pandemic at an individual level. Notably, this population could be at increased occupational risk of acquiring SARS-CoV-2 infection, which ultimately could lead to an increased risk of associated COVID-19 complications. Although it has been emphasized that HCWs with respiratory symptoms should be isolated as soon as possible and protective equipment has been provided in several facilities, there is no consensus on the essential symptoms to promptly identify positive cases to mitigate transmission risks (4). This was previously reported in the Influenza A(H1N1) pandemic in 2009 with the increased risk for influenza in early periods of the pandemic, alongside social disparities, which could represent a challenge to HCWs, particularly in developing countries (5,6).

The situation in Mexico is very particular in that SARS-CoV-2 infection coexists with a high prevalence of comorbidities associated with COVID-19 complications in all patients, including HCWs. Furthermore, healthcare systems within Mexico are highly fragmented and quality of care and the ability to protect HCWs within each institution is highly heterogeneous due to structural inequalities, which overall could increase the disparities in risk among HCWs within marginalized communities (7). Given these fundamental differences, HCWs living in Mexico are at a uniquely substantial risk for SARS-CoV-2 infection and having adverse outcomes. There is a need to understand these trends and outcomes related to COVID-19 to generate evidence that could inform public policy and promote development of recommendations which could improve work environments amongst HCWs by reducing transmission risk and, ultimately improve quality of care. Here, we sought investigate the epidemiology of SARS-CoV-2 infection

within HCWs as well as related outcomes associated with COVID-19 in Mexico City. We also assessed the predictive ability of individual symptoms and comorbidities to identify HCWs with SARS-CoV-2 infection for prompt isolation of affected cases.

## **METHODS**

### *Data sources*

We analyzed data collected within the National Epidemiological Surveillance System database in Mexico City, which is an open-source dataset comprising daily updated suspected COVID-19 cases that have been tested using real-time RT-PCR to confirm SARS-CoV-2 according to the Berlin Protocol (8), and were certified by the National Institute for Diagnosis and Epidemiological Referral (9).

### *Definitions of COVID-19 cases, predictors, and outcomes*

Health-care related professions included subjects whose occupations were reported as physicians, nurses, dentists, laboratory personnel and other involved HCWs. Demographic and health data were collected and uploaded to the epidemiologic surveillance database by personnel from each corresponding health-care facility. Available variables include age, sex, nationality, state and municipality where the case was detected, immigration status as well as identification of individuals belongs to and indigenous group from Mexico. Health information includes the status of diabetes, obesity, chronic obstructive pulmonary disease (COPD), immunosuppression, pregnancy, arterial hypertension, cardiovascular disease, chronic kidney disease (CKD), and asthma. Symptoms included were self-reported fever, cough, odynophagia, dyspnea, irritability, diarrhea, chest pain, shivering, headache, myalgia, arthralgia, malaise, rhinorrhea, polypnea, vomiting, abdominal pain, conjunctivitis, cyanosis, and sudden onset of symptoms. Date of symptom onset, hospital admission, and death are available for all cases as are outpatient or hospitalized status, information regarding the diagnosis of clinical pneumonia, ICU admission, and whether the patient required mechanical

ventilation support (MVS). Severe outcome was defined as a composite definition comprising death, requirement for MVS or ICU admission (10).

### Statistical analysis

#### *Study population*

Categorical variables are presented in frequency distribution with their respective percentage. Continuous variables are presented in mean (standard deviation) or median (interquartile range) wherever appropriate. We compared positive and negative COVID-19 HCWs, alongside with differences amongst positive COVID-19 HCWs using chi-squared tests for categorical variables and Student's t-test or Mann-Whitney's U for continuous variables depending on the variable distribution.

#### *Conditions and symptoms related to SARS-COV-2 positivity*

We aim to investigate related comorbidities and symptoms associated with SARS-COV-2 positivity using logistic regression analyses. We excluded those HCWs who were suspected cases at the time of inclusion. Two separate models were designed to explore related conditions and symptoms associated with positivity. We further explored the diagnostic test capacity, area under the curve, sensitivity, specificity, positive and negative predictive values (VPP, VPN, respectively) of each symptom to predict SARS-CoV-2 positivity.

#### *COVID-19 mortality risk and clinical outcomes*

We fitted Cox Proportional risk regression models to explore risk factors associated to COVID-19 related 30-day lethality, hospitalization, or severe outcome estimating time from symptom onset up to death, clinically reported outcome, or censoring, whichever occurred firsts. Factors associated with using mechanical ventilation support (MVS) were evaluated using logistic regression models. We also performed a Kaplan-Meier analysis to assess differences in COVID-19 outcomes comparing physicians and other HCWs using the Breslow-Cox test. We evaluated Cox Proportional risk regression model performance using Harrel's c-statistic and model assumptions were verified using Schöenfeld residuals. Logistic regression model

performance was evaluated using the Nagelkerke  $R^2$  and the Hosmer-Lemeshow test. A p-value  $<0.05$  was considered as statistical significance threshold. All analyses were performed using R software version 3.6.2.

## RESULTS

### *COVID-19 in health-care workers*

As of the writing of this report (July 2nd, 2020) we identified 34,263 HCWs assessed for SARS-CoV-2. Amongst them, 10,925 (32.9%) had been confirmed with SARS-CoV-2 infection. Overall, positive cases have been increasing since late February, with a notable peak of confirmed cases in late May and early June (**Supplementary Figure 1**). In the group of confirmed cases 4,200 (38.4%) were nurses, 3,244 (29.7%) physicians, 126 (1.15%) dentists, 292 (2.70%) laboratory personnel and 3,063 (28.0%) referred as supportive HCWs. COVID-19 outcomes included 992 (9.08%) HCWs who required hospitalization, 206 with a severe outcome (1.89%), and 90 who required MVS (0.82%). Lethality attributable to COVID-19 was recorded in 224 (2.05%) HCWs. 333 (3.05%) HCWs referred no associated symptomatology but tested positive for SARS-CoV-2. Overall, HCWs had a decreased likelihood to have a positive SARS-COV-2 test (OR 0.72, 95% CI: 0.70-0.74,  $p<0.001$ ) compared with non-HCWs living in Mexico City. Compared with negative cases, those with confirmed SARS-CoV-2 test were older, predominantly female, and with a higher prevalence of diabetes and obesity. As expected, confirmed cases had a higher rate of adverse clinical outcomes (**Table 1**).

### *Associated symptoms and conditions in health-care workers with SARS-CoV-2 positivity*

Symptoms associated with increased probability of SARS-CoV-2 positivity in HCWs included fever, cough, malaise, shivering, myalgias, arthralgias, rhinorrhea, chest pain, and polypnea at the moment of clinical assessment. Conversely, diarrhea, sudden onset of symptoms, irritability, headache were associated with a decreased likelihood of having a positive SARS-CoV-2 test. Next, we sought to investigate the predictive performance of each symptom to predict SARS-CoV-2 positivity; as expected, all symptoms were highly unspecific.

Nevertheless, cases reporting headache, cough, and fever had a higher sensitivity for a positive SARS-CoV-2 test; cyanosis, polypnea, and dyspnea had greatest specificity but with poor sensitivity (**Supplementary Table 1**). We found that pregnancy, male sex, prolonged time for clinical assessment ( $\geq 7$  days since beginning of symptoms), obesity, and diabetes were conditions which increased likelihood of SARS-CoV-2 positivity; whilst active smoking and puerperium had a decreased likelihood of being positive cases (**Figure 1**).

#### *Predictors for COVID-19 related outcomes in health-care workers*

In confirmed SARS-CoV-2 cases, we found that symptoms at clinical assessment which increased risk for hospitalization were dyspnea, fever, and polypnea; while HCWs with diarrhea, odynophagia, and conjunctivitis had a decreased risk for this outcome. Exploring for conditions related to hospitalization, we found that cases with age  $\geq 65$  years, HIV/AIDS, diabetes, obesity, and arterial hypertension had increased risk of being hospitalized. HCWs with age  $\geq 65$  years, dyspnea, fever, or polypnea at the moment of clinical assessment had increased risk for severe outcome. Moreover, age  $\geq 65$  years, diabetes, HIV/AIDS and dyspnea at evaluation were conditions associated with MVS. Predictors of lethality in HCWs were clinical pneumonia at evaluation, age  $\geq 65$  years, diabetes, and obesity (**Figure 2**).

#### *COVID-19 related outcomes of amongst groups of health-care workers.*

Overall, compared with non-HCWs with positive SARS-COV-2 test living in Mexico City, HCWs had a decreased risk for hospitalization (HR: 0.47, 95% CI: 0.44-0.53,  $p < 0.001$ ), severe outcome (HR: 0.41, 95% CI: 0.35-0.47,  $p < 0.001$ ) and lethality (HR: 0.38, 95% CI: 0.32-0.43,  $p < 0.001$ ) (**Figure 3**). Moreover, when we compare HCWs with clinical pneumonia at clinical assessment, we found that this group had a decreased risk for lethality compared with all non-HCWs with or without pneumonia (log-rank  $< 0.001$ , **Supplementary Figure 2**). As a secondary analysis, we sought to explore risk of COVID-19 related outcomes in subgroups of HCWs. Characteristics among physicians, nurses and other HCWs are presented in **supplementary table 2**. Although the group of physicians had a decreased likelihood to have a positive SARS-

COV-2 test (OR 0.75, 95% CI: 0.71-0.79) compared with the group of nurses and other HCWs, this group had an increased risk for hospitalization (HR 1.22, 95%CI: 1.06-1.40,  $p<0.01$ ) and severe outcome (HR 1.56, 95% CI: 1.17-2.10,  $p<0.001$ ) after adjusting for sex, age and comorbidities compared with the group including nurses and other HCWs. Univariate Cox regression model also shown that physicians had an increased lethality risk (HR: 1.53, 95%CI 1.17-2.01,  $p=0.018$ ), which did not sustain significance after adjustment for previously mentioned covariates (**Figure 3**). Finally, a particular group of interest was those HCWs who belonged to an indigenous group, which had up to 11-fold increased risk for COVID-19 lethality (HR 11.44 95%CI 3.57-36.67  $p<0.001$ ) after adjusting for covariates, although no differences were found in the risk for hospitalization and severe outcome.

## DISCUSSION

In this work, we report the prevalence of SARS-CoV-2 infection, related symptomatology, and COVID-19 clinical outcomes using a city-wide based surveillance reports of HCWs living in Mexico City. Our results show that HCWs have decreased propensity for acquiring SARS-CoV-2 infection compared with non-HCWs; nevertheless, amongst health-care workers, the group of physicians tend to have an increased risk severe outcome, which is a remarkable occupational risk. Moreover, certain factors, such as associated comorbidities and symptoms at the time of evaluation may predispose an increased risk of adverse outcomes. These findings should be considered by authorities in relation to relevant occupational hazards in HCWs, particularly in physicians and, given their vital role in diminishing the impact of the pandemic, promote application of stricter regimes to reduce the probability of infection and adverse outcomes attributable to COVID-19 amongst HCWs.

Since the pandemic began, it has been reported that HCWs had an increased incidence of SARS-CoV-2 infection compared with general population, attributable to direct contact during care of hospitalized patients. The prevalence and lethality rate reported in our population is slightly higher compared with previous reports in China, Europe and the United States (4,11–

16). Similarly, in Mexico the number of positive cases reported in HCWs has increased since the first confirmed cases were reported in late February. To reduce transmissibility and improve outcomes, it has been proposed that HCWs who develop respiratory symptoms should be isolated to mitigate the spread between peers. However, as our results confirm and based on previous reports, there is no sustainable evidence which allows using specific symptoms to identify SARS-CoV-2 positive cases in a clinical context (4). Hence, global and local authorities should instead steadily encourage the rational use of personal protective equipment in HCWs, regardless of contact and care for patients with SARS-CoV-2. Although previous reports have shown the effectiveness of personal protective equipment, there is still insufficient evidence if this strategy could mitigate the infection amongst all HCWs at long-term, which sets an area of opportunity for further studies (17,18).

Our results also show that comorbidities in HCWs, particularly those related to chronic non-communicable diseases (e.g., diabetes, obesity and arterial hypertension), and the presentation of severe respiratory symptoms at the time of clinical assessment, increases the risk of adverse COVID-19 outcomes. Certain groups, such as pregnant women, older workers, and those referred to belong to an indigenous group, are at higher risk for severe related outcomes. Previous reports by our group had shown the relationship between the presence of cardiometabolic diseases and risk of complications associated with SARS-CoV-2 infection in Mexico (19–22). Although not completely understood, this relationship could be explained by immunological over responsiveness observed in confirmed cases with diabetes and obesity (19,22,23), particularly given recent evidence relating changes associated with an enhanced immune response to SARS-CoV-2 with risk of respiratory and multi-organ failure (22,24). Conversely, in patients with prior immunosuppression, an increased risk for associated co-infections has been reported, which could explain risk for adverse outcomes in HCWs with HIV/AIDS or pregnancy (25,26).

Finally, we found that physicians are a group of risk for developing adverse events compared to other HCWs. This is consistent with a previous report, as it has been shown that physicians tend to spend more time in areas where patients with SARS-CoV-2 are assisted (27). Furthermore, prolonged shift times, work overload, psychological distress and exposure to probable cases amongst peers could lead physicians to be considered a group with significant occupational risk for developing COVID-19 related outcomes (28–30). Nevertheless, HCWs have overall a lower risk of having a positive test and adverse outcome, compared with other professions. This could be explained by potential factors such as prompt and appropriate medical attention and social assurance which could be provided to HCWs. Interestingly, we also found that groups of physicians who self-reported as belonging to an indigenous community were at increased risk of death attributable to COVID-19. Although preliminary, these results may denote an inequality of access to timely care given the significant social discrepancies reported in Mexico (7,31,32). More studies should focus on the risk of adverse outcomes attributable to social conditions in medical personnel.

Our study had some strengths and limitations. First, we analyzed a large dataset which included information on confirmed positive and negative SARS-CoV-2 cases in Mexico City, providing a unique opportunity to investigate COVID-19 specific risk factors in HCWs. A potential limitation of this study is the use of data collected from a sentinel surveillance system model, which is skewed towards investigating high-risk cases or only those with specific risk factors which on the one hand increases power to detect the effect of comorbidities and on the other hand might not be representative of milder cases of the disease. This is particularly with asymptomatic cases amongst HCWs, which were heavily underrepresented in our study and its prevalence must be assessed with widespread testing amongst HCWs. Another potential limitation of our study is that our assessment of HCWs is limited to those living in Mexico City, which may not capture the whole picture in the country or the large socio-economic inequalities which might lead to higher rates of infection amongst HCWs in disadvantaged areas.

In summary, we present the first report of a city-wide based surveillance system which assessed clinical symptomatology and related outcomes attributable to COVID-19 in HCWs living in Mexico City. We found that no specific symptoms can accurately discern among HCWs with SARS-CoV-2 infection; furthermore, there is a considerable but underreported prevalence of positive asymptomatic infections. We show that comorbidities, presence of respiratory symptoms at clinical assessment, and susceptible groups of HCWs, could have increase the risk of severe outcomes. Our results could inform policies within the health-care systems on the rational use of personal protective equipment, early isolation of probable cases regardless the symptoms, exclusion of risk groups in areas where patients with SARS-CoV-2 are routinely assisted and consideration of intrinsic inequalities between workers, which overall, could bring to a better quality of life for HCWs during the COVID-19 pandemic.

## **ACKNOWLEDGMENTS**

NEAV, JPBL and AVV are enrolled at the PECEM program of the Faculty of Medicine at UNAM. NEAV, JPBL and AVV are supported by CONACyT. The authors would like to acknowledge the invaluable work of all of Mexico's healthcare community in managing the COVID-19 epidemic. Its participation in the COVID-19 surveillance program has made this work a reality, we are thankful for your effort.

## **DATA AVAILABILITY**

All data sources and R code are available for reproducibility of results at [https://github.com/oyaxbell/covid\\_hcws\\_mx](https://github.com/oyaxbell/covid_hcws_mx).

## **AUTHOR CONTRIBUTIONS**

Research idea and study design: NEAV, OYBC; data acquisition: NEAV, OYBC; data analysis/interpretation: NEAV, OYBC, AVV, JPBL; statistical analysis: NEAV, OYBC; manuscript drafting: OYBC, NEAV, AVV, JPBL; supervision or mentorship: OYBC. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions about the accuracy or integrity of any portion of the work are appropriately investigated and resolved.

**FUNDING:** No funding was received.

**CONFLICT OF INTEREST/FINANCIAL DISCLOSURE:** Nothing to disclose.

## **REFERENCES**

1. Clark A, Jit M, Warren-Gash C, Guthrie B, Wang HHX, Mercer SW, et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. *Lancet Glob Heal* [Internet]. 2020 Jun 28; Available from: [https://doi.org/10.1016/S2214-109X\(20\)30264-3](https://doi.org/10.1016/S2214-109X(20)30264-3)
2. Fontanarosa PB, Bauchner H. COVID-19—Looking Beyond Tomorrow for Health Care

- and Society. JAMA [Internet]. 2020 May 19;323(19):1907–8. Available from:  
<https://doi.org/10.1001/jama.2020.6582>
3. King JS. Covid-19 and the Need for Health Care Reform. N Engl J Med [Internet]. 2020 Apr 17;382(26):e104. Available from: <https://doi.org/10.1056/NEJMp2000821>
  4. Clemency BM, Varughese R, Scheafer DK, Ludwig B, Welch J V, McCormack RF, et al. Symptom Criteria for COVID-19 Testing of Health Care Workers. Acad Emerg Med [Internet]. 2020 Jun 1;27(6):469–74. Available from:  
<https://doi.org/10.1111/acem.14009>
  5. Lietz J, Westermann C, Nienhaus A, Schablon A. The Occupational Risk of Influenza A (H1N1) Infection among Healthcare Personnel during the 2009 Pandemic: A Systematic Review and Meta-Analysis of Observational Studies. PLoS One [Internet]. 2016 Aug 31;11(8):e0162061. Available from:  
<https://doi.org/10.1371/journal.pone.0162061>
  6. Córdova-Villalobos JA, Sarti E, Arzoz-Padrés J, Manuell-Lee G, Méndez JR, Kuri-Morales P. The influenza A(H1N1) epidemic in Mexico. Lessons learned. Heal Res policy Syst [Internet]. 2009 Sep 28;7:21. Available from:  
<https://pubmed.ncbi.nlm.nih.gov/19785747>
  7. Puig A, Pagán JA, Wong R. Assessing quality across healthcare subsystems in Mexico. J Ambul Care Manage [Internet]. 2009;32(2):123–31. Available from:  
<https://pubmed.ncbi.nlm.nih.gov/19305224>
  8. <https://datos.cdmx.gob.mx/explore/dataset/base-covid-sinave/table/>. Covid-19 SINAVE Ciudad de México — Datos CDMX.
  9. Secretaría de Salud Subsecretaría de Prevención y Promoción de la Salud Dirección General de Epidemiología. LINEAMIENTO ESTANDARIZADO PARA LA VIGILANCIA EPIDEMIOLÓGICA Y POR LABORATORIO DE LA ENFERMEDAD RESPIRATORIA VIRAL. Apr 1, 2020.

10. Liang W, Liang H, Ou L, Chen B, Chen A, Li C, et al. Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19. *JAMA Intern Med* [Internet]. 2020 May 12; Available from: <https://doi.org/10.1001/jamainternmed.2020.2033>
11. Lai X, Wang M, Qin C, Tan L, Ran L, Chen D, et al. Coronavirus Disease 2019 (COVID-2019) Infection Among Health Care Workers and Implications for Prevention Measures in a Tertiary Hospital in Wuhan, China. *JAMA Netw Open* [Internet]. 2020 May 21;3(5):e209666–e209666. Available from: <https://doi.org/10.1001/jamanetworkopen.2020.9666>
12. Wang Q, Huang X, Bai Y, Wang X, Wang H, Hu X, et al. Epidemiological characteristics of COVID-19 in medical staff members of neurosurgery departments in Hubei province: A multicentre descriptive study. *medRxiv* [Internet]. 2020 Jan 1;2020.04.20.20064899. Available from: <http://medrxiv.org/content/early/2020/04/24/2020.04.20.20064899.abstract>
13. Zheng L, Wang X, Zhou C, Liu Q, Li S, Sun Q, et al. Analysis of the infection status of the health care workers in Wuhan during the COVID-19 outbreak: A cross-sectional study. *Clin Infect Dis* [Internet]. 2020 May 15; Available from: <https://doi.org/10.1093/cid/ciaa588>
14. Korth J, Wilde B, Dolff S, Anastasiou OE, Krawczyk A, Jahn M, et al. SARS-CoV-2-specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients. *J Clin Virol* [Internet]. 2020;128:104437. Available from: <http://www.sciencedirect.com/science/article/pii/S1386653220301797>
15. Lapolla P, Mingoli A, Lee R. Deaths from COVID-19 in healthcare workers in Italy—What can we learn? *Infect Control Hosp Epidemiol*. 2020;1–2.
16. Felice C, Di Tanna GL, Zanusi G, Grossi U. Impact of COVID-19 Outbreak on Healthcare Workers in Italy: Results from a National E-Survey. *J Community Health*

- [Internet]. 2020;45(4):675–83. Available from: <https://doi.org/10.1007/s10900-020-00845-5>
17. Liu M, Cheng S-Z, Xu K-W, Yang Y, Zhu Q-T, Zhang H, et al. Use of personal protective equipment against coronavirus disease 2019 by healthcare professionals in Wuhan, China: cross sectional study. *BMJ* [Internet]. 2020 Jun 10;369:m2195. Available from: <http://www.bmj.com/content/369/bmj.m2195.abstract>
  18. Qaseem A, Etzeandia-Ikobaltzeta I, Yost J, Miller MC, Abraham GM, Obley AJ, et al. Use of N95, Surgical, and Cloth Masks to Prevent COVID-19 in Health Care and Community Settings: Living Practice Points From the American College of Physicians (Version 1). *Ann Intern Med* [Internet]. 2020 Jun 18; Available from: <https://doi.org/10.7326/M20-3234>
  19. Yang JK, Feng Y, Yuan MY, Yuan SY, Fu HJ, Wu BY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. *Diabet Med* [Internet]. 2006;23(6):623–8. Available from: <http://europepmc.org/abstract/MED/16759303>
  20. Guan W, Liang W, Zhao Y, Liang H, Chen Z, Li Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. *Eur Respir J* [Internet]. 2020 Jan 1;2000547. Available from: <http://erj.ersjournals.com/content/early/2020/03/17/13993003.00547-2020.abstract>
  21. Bello-Chavolla OY, Bahena-López JP, Antonio-Villa NE, Vargas-Vázquez A, González-Díaz A, Márquez-Salinas A, et al. Predicting mortality due to SARS-CoV-2: A mechanistic score relating obesity and diabetes to COVID-19 outcomes in Mexico. *J Clin Endocrinol Metab* [Internet]. 2020 May 31; Available from: <https://doi.org/10.1210/clinem/dgaa346>
  22. Stefan N, Birkenfeld AL, Schulze MB, Ludwig DS. Obesity and impaired metabolic health in patients with COVID-19. *Nat Rev Endocrinol* [Internet]. 2020;16(7):341–2.

Available from: <https://doi.org/10.1038/s41574-020-0364-6>

23. Chen X, Hu W, Ling J, Mo P, Zhang Y, Jiang Q, et al. Hypertension and Diabetes Delay the Viral Clearance in COVID-19 Patients. medRxiv [Internet]. 2020 Jan 1;2020.03.22.20040774. Available from: <http://medrxiv.org/content/early/2020/03/24/2020.03.22.20040774.abstract>
24. Klonoff DC, Umpierrez GE. Letter to the Editor: COVID-19 in patients with diabetes: Risk factors that increase morbidity. Metabolism [Internet]. 2020/04/07. 2020 Jul;108:154224. Available from: <https://pubmed.ncbi.nlm.nih.gov/32275971>
25. Rasmussen SA, Smulian JC, Lednický JA, Wen TS, Jamieson DJ. Coronavirus Disease 2019 (COVID-19) and pregnancy: what obstetricians need to know. Am J Obstet Gynecol [Internet]. 2020 May 1;222(5):415–26. Available from: <https://doi.org/10.1016/j.ajog.2020.02.017>
26. Shiao S, Krause KD, Valera P, Swaminathan S, Halkitis PN. The Burden of COVID-19 in People Living with HIV: A Syndemic Perspective. AIDS Behav [Internet]. 2020 Apr 18;1–6. Available from: <https://pubmed.ncbi.nlm.nih.gov/32303925>
27. Manzoni P, Milillo C. Covid-19 mortality in Italian doctors. J Infect [Internet]. 2020 May 21;S0163-4453(20)30311-X. Available from: <https://pubmed.ncbi.nlm.nih.gov/32445726>
28. Huang JZ, Han MF, Luo TD, Ren AK, Zhou XP. Mental health survey of 230 medical staff in a tertiary infectious disease hospital for COVID-19. Zhonghua lao dong wei sheng zhi ye bing za zhi= Zhonghua laodong weisheng zhiyebing zazhi= Chinese J Ind Hyg Occup Dis. 2020;38:E001–E001.
29. Huang F, Yang Z, Wang Y, Zhang W, Lin Y, Zeng L, et al. Study on health-related quality of life and influencing factors of pediatric medical staff during the COVID-19 outbreak. 2020;
30. Du J, Dong L, Wang T, Yuan C, Fu R, Zhang L, et al. Psychological symptoms among

frontline healthcare workers during COVID-19 outbreak in Wuhan. *Gen Hosp*

*Psychiatry*. 2020;

31. Barraza-Lloréns M, Bertozzi S, González-Pier E, Gutiérrez JP. Addressing Inequity In Health And Health Care In Mexico. *Health Aff [Internet]*. 2002 May 1;21(3):47–56.  
Available from: <https://doi.org/10.1377/hlthaff.21.3.47>
32. Bello-Chavolla OY, González-Díaz A, Antonio-Villa NE, Fermín-Martínez CA, Márquez-Salinas A, Vargas-Vázquez A, et al. Unequal impact of structural health determinants and comorbidity on COVID-19 severity and lethality in older Mexican adults: Looking beyond chronological aging. *medRxiv [Internet]*. 2020 Jan 1;2020.05.12.20098699.  
Available from:  
<http://medrxiv.org/content/early/2020/05/18/2020.05.12.20098699.abstract>

## TABLES

**TABLE 1:** Characteristics of health-care workers with and without positive COVID-19 living in Mexico. *Abbreviations:* COPD= Chronic obstructive pulmonary disease; HIV/AIDS= Human immunodeficiency virus and/or acquired immunodeficiency syndrome; CKD= Chronic kidney disease.


Parameter	Health-Care Workers	Health-Care Workers	P value
	with COVID (n=10,925)	without COVID (n=23,338)	
Female sex (%)	6,547 (59.9)	15,007 (64.3)	<0.001
Age (years)	40.2 ( $\pm$ 10.7)	39.9 ( $\pm$ 10.9)	<0.001
Physicians (%)	3,244 (29.7)	7,972 (34.2)	<0.001
Nurses (%)	4,200 (38.4)	8,305 (35.6)	<0.001
Dentists (%)	126 (1.15)	352 (1.51)	0.007
Laboratory personnel (%)	292 (2.70)	481 (2.06)	<0.01
Other HCWs (%)	3,063 (28.0)	6,228 (26.7)	0.020
Mortality (%)	224 (2.05)	95 (0.41)	<0.001
Hospitalizacion (%)	992 (9.08)	940 (4.03)	<0.001

Severe Outcome	206 (1.89)	191 (0.81)	<0.001
Clinical pneumonia (%)	1,207 (11.0)	1,199 (5.14)	<0.001
Mechanical-Ventilation (%)	90 (0.82)	54 (0.23)	<0.001
≥7 days since beginning of symptoms (%)	2,208 (20.2)	3,618 (15.5)	<0.001
Diabetes (%)	762 (7.0)	1,280 (5.50)	<0.001
COPD (%)	60 (0.55)	129 (0.55)	0.926
Asma (%)	428 (3.92)	991 (4.25)	0.255
HIV/AIDS (%)	31 (0.28)	84 (0.36)	0.493
Obesity (%)	2,041 (18.7)	3,491 (14.9)	<0.001
Smoking status (%)	1,023 (9.37)	2,293 (9.84)	0.149
CKD (%)	61 (0.56)	101 (0.43)	0.213
Pregnant women (%)	37 (0.34)	48 (0.21)	0.243
Indigenous (%)	40 (0.37)	99 (0.43)	0.203


---

## FIGURES


**Figure 1:** Associated symptoms (A) and conditions (B) at clinical assessment of COVID-19 in Health-Care Workers. *Abbreviations:* OR= Odds ratio; 95%CI= 95% confidence interval.



**Figure 2:** Risk factors associated to hospitalization (A), severe outcome (B), MVS (C) and lethality associated to COVID-19 in health-care workers with SARS-CoV-2 in Mexico City. Abbreviations: MVS= Mechanical ventilation support.



**Figure 3:** Kaplan-Meier survival plot to identify the risk of hospitalization (A-D), severe outcome (B-E) and lethality (C-F) in HCWs compared with other non-HCWs and between physicians and nurses and other HCW.



**Supplementary Table 1:** Predictive test values among health-care workers living in Mexico City to identify positive SARS-CoV-2 test.

Abbreviations: AUC= Area under the curve; ACC= Accuracy; SE= Sensitivity; SPE= Specificity; PLR= Positive likelihood ratio; NLR= Negative likelihood ratio; PPV= Positive predictive value; NPV= Negative predictive value.

Parameter	AUC	ACC	SE	SPE	PLR	NLR	PPV	NPV
Fever	0.618 (0.612-0.624)	0.606	0.651 (0.642-0.660)	0.585 (0.578-0.591)	1.568 (1.536-1.602)	0.597 (0.580-0.614)	0.427 (0.419-0.435)	0.779 (0.773-0.785)
Cough	0.579 (0.574-0.584)	0.512	0.769 (0.761-0.777)	0.389 (0.383-0.396)	1.259 (1.240-1.278)	0.593 (0.571-0.617)	0.374 (0.368-0.381)	0.780 (0.772-0.788)
Odynophagia	0.534 (0.528-0.540)	0.530	0.545 (0.536-0.555)	0.522 (0.516-0.529)	1.141 (1.116-1.167)	0.871 (0.850-0.892)	0.352 (0.344-0.359)	0.707 (0.700-0.714)
Dyspnea	0.531 (0.527-0.536)	0.646	0.209 (0.202-0.217)	0.853 (0.849-0.858)	1.428 (1.360-1.500)	0.926 (0.916-0.937)	0.404 (0.391-0.417)	0.694 (0.689-0.700)
Irritability	0.514 (0.510-0.519)	0.636	0.172 (0.165-0.180)	0.856 (0.851-0.861)	1.198 (1.137-1.264)	0.967 (0.957-0.977)	0.363 (0.350-0.376)	0.685 (0.680-0.691)
Diarrhea	0.521 (0.516-0.526)	0.617	0.251 (0.242-0.259)	0.792 (0.786-0.797)	1.202 (1.153-1.254)	0.947 (0.935-0.959)	0.364 (0.353-0.375)	0.690 (0.684-0.695)
Chest pain	0.544 (0.538-0.549)	0.633	0.292 (0.283-0.300)	0.795 (0.790-0.801)	1.425 (1.369-1.483)	0.891 (0.878-0.903)	0.404 (0.393-0.415)	0.702 (0.697-0.708)
Shivering	0.582 (0.576-0.588)	0.625	0.461 (0.452-0.471)	0.703 (0.696-0.709)	1.551 (1.507-1.597)	0.767 (0.752-0.782)	0.425 (0.416-0.434)	0.732 (0.726-0.738)
Headache	0.538 (0.533-0.543)	0.439	0.816 (0.809-0.824)	0.260 (0.254-0.266)	1.103 (1.090-1.116)	0.706 (0.674-0.740)	0.344 (0.338-0.350)	0.749 (0.739-0.758)

Myalgia	0.594 (0.588-0.600)	0.571	0.658 (0.649-0.667)	0.530 (0.523-0.537)	1.400 (1.372-1.428)	0.646 (0.627-0.665)	0.400 (0.393 0.408)	0.765 (0.758 -0.771)
Arthralgia	0.595 (0.589-0.601)	0.591	0.605 (0.595-0.614)	0.585 (0.578-0.591)	1.457 (1.425-1.489)	0.676 (0.658-0.694)	0.410 (0.402-0.418)	0.756 (0.750-0.763)
Malaise	0.593 (0.587-0.598)	0.605	0.557 (0.547-0.566)	0.629 (0.622-0.635)	1.499 (1.463-1.536)	0.705 (0.689-0.722)	0.416 (0.408-0.424)	0.749 (0.742-0.755)
Rhinorrhea	0.546 (0.540-0.551)	0.598	0.400 (0.390-0.409)	0.691 (0.685-0.698)	1.296 (1.256-1.336)	0.868 (0.852-0.884)	0.381 (0.372-0.390)	0.381 (0.372-0.390)
Polypnea	0.517 (0.514-0.520)	0.672	0.079 (0.074-0.084)	0.954 (0.951-0.957)	1.722 (1.574-1.883)	0.965 (0.959-0.971)	0.450 (0.427-0.473)	0.686 (0.680-0.691)
Vomiting	0.511 (0.508 0.514)	0.669	0.065 (0.061-0.070)	0.957 (0.954-0.959)	1.512 (1.373-1.664)	0.977 (0.971-0.983)	0.418 (0.394 0.442)	0.683 (0.678-0.688)
Abdominal pain	0.512 (0.508 0.516)	0.643	0.145 (0.138-0.152)	0.879 (0.875-0.884)	1.203 (1.134-1.276)	0.972 (0.963 -0.981)	0.364 (0.349 0.379)	0.684 (0.678 0.689)
Conjunctivitis	0.515 (0.511-0.519)	0.641	0.160 (0.153-0.167)	0.870 (0.865-0.874)	1.230 (1.163 -1.301)	0.966 (0.956 -0.975)	0.369 (0.355-0.383)	0.685 (0.680 -0.691)
Cyanosis	0.504 (0.502-0.506)	0.674	0.026 (0.023 -0.029)	0.982 (0.981-0.984)	1.469 (1.259-1.715)	0.992 (0.988-0.995)	0.411 (0.374-0.449)	0.679 (0.674-0.685)
Sudden Onset of Symptoms	0.540 (0.534-0.546)	0.590	0.397 (0.387 -0.406)	0.683 (0.677-0.690)	1.253 (1.215 1.292)	0.883 (0.867-0.899)	0.377 (0.367-0.386)	0.701 (0.695-0.708)

---

**Supplementary Table 2:** Characteristics amongst health-care workers with positive SARS-CoV-2 test living in Mexico City.


*Abbreviations:* COPD= Chronic obstructive pulmonary disease; HIV/AIDS= Human immunodeficiency virus and/or acquired immunodeficiency syndrome; CKD= Chronic kidney disease. \*Other HCWs include: 126 (3.61%) dentists, 292 (8.38%) laboratorians and 3,063 (87.9%) other related HCWs.

<b>Parameter</b>	<b>Physicians (n=3,244)</b>	<b>Nurses (n=4,200)</b>	<b>Other HCW* (n=3,481)</b>	<b>P value</b>
Female sex (%)	1,452 (44.8)	3,277 (78.0)	1,818 (52.2)	<0.001
Age (years)	41.2 (12.2)	38.9 (9.7)	40.8 (10.3)	<0.001
Mortality (%)	109 (3.36)	32 (0.76)	83 (2.40)	<0.001
Hospitalization (%)	393 (12.1)	283 (6.73)	316 (9.10)	<0.001
Clinical pneumonia (%)	427 (13.2)	375 (8.93)	405 (11.6)	<0.001
Severe Outcome (%)	93 (2.90)	51 (1.21)	62 (1.78)	<0.001
Mechanical-Ventilation (%)	49 (1.51)	13 (0.31)	28 (0.80)	<0.001
≥7 days since beginning of symptoms (%)	575 (17.7)	885 (21.1)	748 (21.5)	<0.001


Diabetes (%)	243 (7.50)	279 (6.65)	240 (6.90)	0.304
COPD (%)	19 (0.59)	19 (0.45)	22 (0.63)	0.436
Asma (%)	181 (5.58)	138 (3.29)	109 (3.13)	<0.001
HIV/AIDS (%)	7 (0.21)	9 (0.21)	15 (0.43)	0.137
Obesity (%)	493 (15.2)	847 (20.2)	701 (20.1)	<0.001
Smoking status (%)	224 (6.91)	369 (8.80)	430 (12.4)	<0.001
CKD (%)	20 (0.62)	20 (0.48)	21 (0.61)	0.505
Pregnant women (%)	7 (0.22)	19 (0.45)	11 (0.32)	<0.01
Indigenous (%)	13 (0.41)	18 (0.44)	9 (0.26)	0.497



---





**Supplementary Figure 1:** Density plot of positive and negative cases amongst health-care workers since the beginning of the pandemic in Mexico.




**Supplementary Figure 2:** Kaplan-Meier survival plot to identify the risk of lethality attributable to COVID-19 in health care professionals and non-health-care workers with and without clinical pneumonia.




**A****B**



**A** Hospitalization Risk in Mexico City Workers with SARS-CoV-2


Number at risk

Strata	0	5	10	15
Other professions	49196	22582	5498	700
Health-Care Workers	10925	3973	809	138

**B** Severe Outcome Risk in Mexico City Workers with SARS-CoV-2


Number at risk

Strata	0	5	10	15
Other professions	49196	22582	5498	700
Health-Care Workers	10925	3973	809	138

**C** Lethality Risk in Mexico City Workers with SARS-CoV-2


Number at risk

Strata	0	5	10	15	20	25
Other professions	49195	22086	7788	2706	1099	569
Health-Care Workers	10925	4327	1165	227	81	46

**D** Hospitalization Risk in Health-Care Workers with SARS-CoV-2


Number at risk

Strata	0	5	10	15
Nurses & Others Health-Care Workers	7681	2883	595	104
Physicians	3244	1090	214	34

**E** Severe Outcome in Health-Care Workers with SARS-CoV-2

Number at risk

Strata	0	5	10	15
Nurses & Others Health-Care Workers	7681	2883	595	104
Physicians	3244	1090	214	34

**F** Lethality Risk in Health-Care Workers with SARS-CoV-2

Number at risk

Strata	0	5	10	15	20	25
Nurses & Others Health-Care Workers	7681	3015	791	137	44	28
Physicians	3244	1312	374	90	37	18